Elekta’s Clarity soft tissue visualization system cleared for use for cancer patients in China

Men with prostate cancer will be the first group of patients in China to benefit from the recent clearance of Elekta’s (EKTA-B.ST) Clarity™ soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta’s premiere linear accelerator offering, Versa HD™, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.

Beijing China — Tuesday, November 4, 2014
“As radiation oncology equipment becomes increasingly available to Chinese clinicians, and as demand grows, Elekta is providing world-class solutions, such as Clarity, to meet the specific needs of this market,” says Anming Gong, Elekta’s Managing Director for China.
The authorization for Clarity use in China follows the CFDA’s clearance in September of Elekta’s Versa HD™ linear accelerator, enabling Elekta to sell and market the system in China.
According to the International Agency for Research on Cancer, well over three million people are diagnosed with cancer every year in China1. Prostate cancer is the sixth most common cancer for men in China2
1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

2. GLOBOCAN 2012 (IARC) (http://globocan.iarc.fr/Pages/fact_sheets_population.aspx




About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com Twitter: @Elekta.

Press Releases

For further information, please contact

Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242
Email: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Kris Walmsley, Corporate Communications Manager, Elekta ABTel: +46 70 537 9545
Email: kris.walmsley@elekta.comTime zone: CET: Central European Time